Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RuPiXiao is a widely utilized Traditional Chinese Medicine (TCM) compound formula primarily indicated for the treatment of hyperplasia of mammary glands (breast hyperplasia), acute mastitis, and breast lumps. The formula typically comprises 15 herbal and animal-derived ingredients, including *Cornu Cervi* (antler), *Herba Taraxaci* (dandelion), *Sargassum* (seaweed), and *Spica Prunellae* (selfheal spike). According to TCM principles, it functions to clear heat, detoxify, activate blood circulation to resolve stasis, and soften hardness to dissipate nodules. Clinically, RuPiXiao is used to regulate the endocrine system by balancing estrogen and progesterone levels and exhibits anti-inflammatory and analgesic properties. It is often compared to other TCM treatments like Xiaopiruanfang in clinical trials for breast enlargement and mammary gland disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rupixiao.